The role of COX-2 in intestinal inflammation and colorectal cancer

D. Wang, R. N. Dubois

Research output: Contribution to journalArticle

449 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC. As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is associated with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC. The epidemiological studies, clinical trials and animal experiments indicate that NSAIDs are among the most promising chemopreventive agents for this disease. NSAIDs exert their anti-inflammatory and antitumor effects primarily by reducing prostaglandin production by inhibition of COX-2 activity. In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease. These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment.

Original languageEnglish (US)
Pages (from-to)781-788
Number of pages8
JournalOncogene
Volume29
Issue number6
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Intestinal Neoplasms
Cyclooxygenase 2
Colorectal Neoplasms
Inflammation
Anti-Inflammatory Agents
Cyclooxygenase 2 Inhibitors
Pharmaceutical Preparations
Colitis
Inflammatory Bowel Diseases
Epigenomics
Prostaglandins
Life Style
Epidemiologic Studies
Neoplasms
Research Personnel
Clinical Trials
Diet
Mutation
Survival

Keywords

  • Colorectal cancer
  • Cyclooxygenase
  • Inflammation
  • NSAIDs
  • Prostaglandins

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

The role of COX-2 in intestinal inflammation and colorectal cancer. / Wang, D.; Dubois, R. N.

In: Oncogene, Vol. 29, No. 6, 02.2010, p. 781-788.

Research output: Contribution to journalArticle

Wang, D. ; Dubois, R. N. / The role of COX-2 in intestinal inflammation and colorectal cancer. In: Oncogene. 2010 ; Vol. 29, No. 6. pp. 781-788.
@article{5dd742eaa6ce4076be9eeb2369467645,
title = "The role of COX-2 in intestinal inflammation and colorectal cancer",
abstract = "Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC. As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is associated with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC. The epidemiological studies, clinical trials and animal experiments indicate that NSAIDs are among the most promising chemopreventive agents for this disease. NSAIDs exert their anti-inflammatory and antitumor effects primarily by reducing prostaglandin production by inhibition of COX-2 activity. In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease. These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment.",
keywords = "Colorectal cancer, Cyclooxygenase, Inflammation, NSAIDs, Prostaglandins",
author = "D. Wang and Dubois, {R. N.}",
year = "2010",
month = "2",
doi = "10.1038/onc.2009.421",
language = "English (US)",
volume = "29",
pages = "781--788",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The role of COX-2 in intestinal inflammation and colorectal cancer

AU - Wang, D.

AU - Dubois, R. N.

PY - 2010/2

Y1 - 2010/2

N2 - Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC. As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is associated with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC. The epidemiological studies, clinical trials and animal experiments indicate that NSAIDs are among the most promising chemopreventive agents for this disease. NSAIDs exert their anti-inflammatory and antitumor effects primarily by reducing prostaglandin production by inhibition of COX-2 activity. In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease. These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment.

AB - Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC. As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is associated with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC. The epidemiological studies, clinical trials and animal experiments indicate that NSAIDs are among the most promising chemopreventive agents for this disease. NSAIDs exert their anti-inflammatory and antitumor effects primarily by reducing prostaglandin production by inhibition of COX-2 activity. In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease. These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment.

KW - Colorectal cancer

KW - Cyclooxygenase

KW - Inflammation

KW - NSAIDs

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=76849095665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76849095665&partnerID=8YFLogxK

U2 - 10.1038/onc.2009.421

DO - 10.1038/onc.2009.421

M3 - Article

C2 - 19946329

AN - SCOPUS:76849095665

VL - 29

SP - 781

EP - 788

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 6

ER -